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Abstract
Background: Percutaneous atrial septal defect (ASD) closure is a routine procedure to prevent right 
ventricular failure, pulmonary hypertension, or paradoxical embolism. The latter is the typical reason 
for percutaneous patent foramen ovale (PFO) closure. Atrial enlargement represents a risk for develop-
ing atrial fibrillation (AF). Percutaneous left atrial appendage (LAA) closure is emerging as a preven-
tive therapy for patients in AF who suffered from a previous stroke or bleeding (secondary prevention) 
or patients without previous stroke or bleeding (primary prevention). Percutaneous septal closure, 
particularly that of large ASDs, may inhibit future percutaneous left atrial access when required for 
LAA closure. Reported herein is the feasibility and safety of concomitant percutaneous closure of the 
LAA and a septal shunt, mostly large ASDs, in patients without AF, in the sense of “primary primary” 
preventive LAA closure. The first “primary” relates to “in anticipation of AF” and potentially also for 
“for prevention of AF”. The second “primary” relates to “prevention of stroke or bleeding”.
Methods: Thirteen consecutive patients, older than 40 years without any clinical or electrocardio-
graphic evidence of AF, underwent percutaneous closure of large ASDs or PFOs in the presence of 
enlarged atria at the university hospitals of Bern and Zurich between April 2013 and June 2015. They 
concomitantly received “primary primary” preventive LAA closure after informed consent. 
Results Mean patient age was 58 ± 9 years (46% male). Procedural success was achieved in all pa-
tients and no major adverse events occurred acutely or during the following 2.0 ± 0.8 years. No patient 
developed AF.
Conclusions: Concomitant closure of ASD or PFO in the presence of enlarged atria and LAA for 
“primary primary” prevention appears feasible and safe but has yet to prove its justification. (Cardiol J  
2018; 25, 2: 179–187)
Key words: atrial fibrillation, atrial septal defect closure, patent foramen ovale closure, 
left atrial appendage closure
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Introduction
Atrial septal defect (ASD) is one of the most 
frequent congenital heart defects [1]. While the 
only risk of small ASDs is paradoxical embolism, 
sequelae of larger ASDs comprise pulmonary hy-
pertension, congestive heart failure, and atrial ar-
rhythmia, in particular atrial fibrillation (AF) [2–5]. 
Percutaneous ASD closure is the treatment of 
choice for ASDs to prevent such adverse outcome 
and to improve exertional dyspnea [6–8]. Percu-
taneous ASD closure is an overall safe procedure 
but it carries a potential risk for developing AF by 
device irritation of the septum [9–11]. Although 
such new onset AF typically occurs only in the 
first few weeks after device implantation [9, 12], 
patients undergoing percutaneous closure of large 
ASDs are temporarily at a double risk for develop-
ing AF, 1) due to septal device irritation and 2) due 
to the preexisting atrial enlargement. Subsequent 
reduction of atrial diameters after shunt elimina-
tion reduces the risk for AF. A net benefit in that 
respect can be expected but the overall risk for AF 
of such patients remains elevated. The situation 
is similar for patients with a patent foramen ovale 
(PFO) and enlarged atria.
In AF, left atrial appendage (LAA) closure has 
emerged as an alternative to medical therapy in 
the form of chronic oral anticoagulation (COA) for 
stroke or bleeding prevention. While closure of the 
LAA comes at the price of 2–7% procedural adverse 
events, it shows a significant reduction in major 
bleeding events at a similar stroke rate compared 
to COA [13–16]. After 4 years of follow-up, closure 
of the LAA even showed significantly improved 
survival in randomized comparisons [17, 18]. 
Closure of the LAA so far has been exclusively 
performed in patients with documented AF, either 
for primary prevention (patients with AF without 
previous embolic ischemic event or bleeding) 
or secondary prevention (patients with AF with 
a previous embolic ischemic event or bleeding). 
Percutaneous closure of septal defects, par-
ticularly large ASDs, hinders future percutaneous 
transseptal left atrial access although it remains 
possible at least in the case of smaller ASD [19] or 
PFO devices [20]. Even if such patients never had 
AF, their risk for developing AF during follow-up 
is 2-fold higher after ASD closure than that of the 
general population [21] and also increased after 
PFO closure in the presence of enlarged atria.
Herein reported is the first experience with 
concomitant percutaneous closure of LAA at the 
time of closure of ASDs or PFOs in the presence 
of enlarged atria in patients without history of AF. 
They were considered at increased risk for later AF, 
particularly in the initial phase after septal shunt 
closure due to septal device irritation while atrial 
dimensions have not yet shrunk after volume un-
load. It is referred to in this procedure as “primary 
primary” preventive LAA closure, i.e., LAA closure 
for primary prevention (in anticipation of AF or 
even preventing AF) and for primary prevention 
of stroke or bleeding, should AF occur.
Methods
Population
This is a retrospective study of consecutive 
patients (≥ 40 years) undergoing percutaneous 
closure of a large ASD (≥ 20 mm) or a PFO with 
large atria (left atrium [LA] ≥ 40 mm, parasternal 
long axis) and at the same time of the LAA. Pa-
tients neither had clinical or electrocardiographic 
signs of prior AF nor an AF associated embolic 
ischemic or bleeding event. In the patients with 
prior ischemic events, AF had been excluded 
by long-term electrocardiogram (ECG). Patients 
consented to both procedures (ASD closure and 
LAA closure) separately and also to data collec-
tion. The potential benefits and risks of “primary 
primary” preventive LAA closure was discussed 
extensively with the patients. The local institu-
tional review boards approved data collection of 
clinically indicated investigations during follow-up. 
The procedures were performed at the university 
hospitals of Bern and Zurich. Demographic and 
clinical characteristics, including risk for stroke 
and major bleeding (CHA2DS2-VASc score, HAS-
-BLED score), procedural data, and outcome data 
of in-hospital and follow-up periods were captured 
from medical records and patient contact.
Procedure
All procedures were performed under fluo-
roscopy guidance without echocardiography [15, 
22, 23]. All patients had had transesophageal 
echocardiography (TEE) during their workups. 
Computer tomography was not used. Oral anti-
biotics (2–3 doses) were given before and after 
the procedure and all patients received 5000 units 
of intravenous heparin at the beginning of the 
procedure. All procedures were done using Am-
platzer devices (Amplatzer Cardiac Plug (ACP), 
Amplatzer Amulet Occluder, Amplatzer Septal 
Occluder (ASO), Amplatzer Cribriform Occluder, 
or Amplatzer PFO Occluder, Abbott, St. Paul, MN, 
USA). Figures 1–4 provide examples. LAA closure 
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Figure 1. Simultaneous closure of the left atrial appendage (LAA) and an atrial septal defect (ASD) in a 55-year- 
-old male with exertional dyspnea and a newly detected large ASD secundum but no history of atrial fibrillation. 
A. Overinflated 34 mm Amplatzer sizing balloon in ASD, measuring 38 mm at the waist representing the ASD; 
B. Contrast medium injection into the LAA through a 13 French (F) TorqView sheath in a right anterior oblique projection; 
C. Implantation of a 28 mm Amplatzer Cardiac Plug (ACP) through this sheath; D. Implantation of a 40 mm Amplatzer 
Septal Occluder (ASO) through the same sheath in a left anterior oblique projection. The right atrium (RA) is filled 
with contrast medium; E. Same view during the levophase with the left atrium (LA) delineated (dotted line) by con-
trast medium; F. Three-dimensional (3D) transesophageal echocardiography (TEE) before the procedure depicting 
the ASD; G. Two-dimensional (2D) TEE before the procedure indicating an ASD diameter of 28 mm; H. 2D TEE at 
11-month follow-up depicting the ASD and LAA occluders; I. 3D TEE at 11-month follow-up. The ASO occludes the 
ASD completely without evidence of thrombus.
Figure 2. Transesophageal echocardiography of a 53-year-old woman with exertional dyspnea and chest pain and 
a newly detected secundum atrial septal defect (ASD) as well as a patent foramen ovale (PFO) but no history of atrial 
fibrillation. The coronary arteries were normal on the incidental angiogram. The insert shows the result after simulate-
nous device closure of ASD (26 mm Amplatzer Septal Occluder), PFO (30 mm Amplatzer Cribriform Occluder), and 
left atrial appendage (LAA, 22 mm Amplatzer Amulet) Occluder; LV — left ventricle; RV — right ventricle.
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was performed before septal closure. After cross-
ing the septal defect from the right femoral vein, 
a 0.035” Backup wire (Boston Scientific, Natick, MA, 
USA) was placed in the LA. A 34 mm Amplatzer 
sizing balloon was placed across ASDs and inflated 
to aid eyeball sizing of the defect. The balloon was 
removed. Over the Backup wire, the 14 French 
(F) 45° × 45° Amplatzer TorqVue delivery sheath 
was introduced. The LAA was engaged in a right 
anterior oblique (RAO) view and contrast injections 
were performed in RAO caudal and cranial views. 
Sizing was done by eyeballing the outer diameter 
of the delivery sheath (12 F: 4.5 mm, 13 F: 5.0 mm, 
and 14 F: 5.5 mm) served as reference. About 
20–50% oversizing was the rule [15]. Stability of 
the device was assessed by a tug test and by angio-
graphic imaging with contrast medium injections 
in 2 views showing the device in profile without 
overlap of the 2 device components. After release 
of the LAA occluder, the TorqVue sheath was left in 
the LA and the appropriately sized septal occluder 
(aiming for at least 30% oversizing in ASDs) was 
attached to the same delivery cable and introduced 
through the sheath. In case of ASDs, the left atrial 
disc was fully and the right atrial disc partially 
deployed in the LA. This technique forces the 
ASO to self-center in the defect. The pulling of the 
right disc trough, the defect was observed based 
on the migrating of the lower device indentation in 
a left anterior oblique (LAO) projection before the 
right atrial disc was fully deployed. Correct device 
position was confirmed by LAO contrast medium 
injections and a robust wiggle of the device. The 
sheath was removed and the puncture site was 
manually compressed by the patient unless a simul-
taneous arterial puncture mandated compression 
Figure 3. Simultaneous closure of patent foramen ovale (PFO), atrial septal defect (ASD), and left atrial appendage 
(LAA) in patient of Figure 2; A. Sizing balloon in PFO; B. Sizing balloon in ASD, wire through PFO; C. Contrast medium 
injection into LAA through 12 French (F) TorqVue sheath in a right anterior oblique projection; D. LAA occluded (with 
22 mm Amplatzer Amulet Occluder); E. Final result: LAA occluded with 22 mm Amplatzer Amulet Occluder (22), 
then PFO occluded with 30 mm Amplatzer Cribriform Occluder (30), and finally ASD occluded with 26 mm Amplatzer 
Septal Occluder (26). Left anterior oblique projection; LA — left atrium; RA — right atrium.
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by a medical person. Before discharge the same or 
the following day, transthoracic echocardiography 
was performed to assure the correct position of the 
devices and to exclude pericardial effusion. There 
were no recommendations for physical restrictions 
of any sort.
Post interventional antithrombotic regimen 
comprised clopidogrel 75 mg for 1–3 months and 
acetylsalicylic acid 100 mg for 5–6 months. Control 
TEE was recommended after 3–6 months to assess 
for device thrombi and residual shunts or leaks.
Outcome
The composite endpoint was defined according 
to Valve Academic Research Consortium (VARC)-2 
criteria [24]. The primary safety endpoint was 
defined as death related to closure of the LAA, 
procedure-related ischemic stroke, hemorrhagic 
stroke, cardiac tamponade, need for urgent sur-
gery (e.g., due to embolization of the device, 
repair of procedure-related injury, or bleeding) 
and major or life-threatening bleeding (accord-
ing to VARC-2 criteria). The primary efficacy 
endpoint was defined as stroke (non-disabling, 
disabling, ischemic, or hemorrhagic), systemic 
embolization, or cardiovascular or unexplained 
death. New-onset of AF was looked for clinically 
and by (24-h) ECG. Clinical follow-up data were 
obtained reviewing medical records and by con-
tacting patients.
Figure 4. Simultaneous closure of the left atrial appendage (LAA) and a newly detected double atrial septal defect 
(ASD) in a 64-year-old male with dyspnea but no atrial fibrillation. All devices were implanted through the same 
14 French TorqVue sheath; A. 40 mm Amplatzer Septal Occluder (ASO, 40), 18 mm ASO (18), and 16 mm Amplatzer 
Amulet Occluder (16) depicted in a in a left anterior oblique projection. The right atrium (RA) and in the insert the left 
atrium (LA) are filled with contrast medium; B. Double ASD in a transesophageal echocardiography (TEE) before the 
intervention; C. Double ASD in a three-dimensional TEE 4 months after the intervention with the two ASOs in place.
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Statistical analysis 
Data are expressed as mean and standard de-
viation for continuous variables and as number and 
percentage for categorical variables. Analysis was 
performed using a standard statistical software pro-
gram (SPSS, version 23; IBM, Armonk, NY, USA). 
Results
Baseline characteristics
Thirteen patients were included between April 
2013 and June 2015. Patients were 58 ± 9 years 
old (54% women). Baseline characteristics are 
described in Table 1. No patient had any history of 
AF. Three patients had a previous history of isch-
emic cerebrovascular events. The total procedural 
fluoroscopy time was 16 ± 8 min (Table 2).
Device success
In all patients ASD or PFO and LAA closures 
were successful. In 1 patient, 2 ASDs and in 1 pa-
tient, a PFO in addition to an ASD were present 
and closed with 2 separate devices (Figs. 2, 3). No 
periprocedural complications occurred (Table 2). 
Clinical follow-up
Length of hospital stay was 1 night in 9 pa-
tients and the remaining 4 patients were discharged 
the same day. TEE follow-up was available after 
6.7 ± 2.0 months in 10 patients. No device-related 
complications occurred (Table 3). One patient 
needed a re-intervention because of 2 residual 
ASD shunts at follow up. Re-intervention was suc-
cessfully performed under fluoroscopy only using 
a 25 mm and a 18 mm PFO Occluder at 6 months 
after initial procedure. At clinical follow-up of 
2.0 ± 0.8 years, no adverse events had occurred, 
no patient had reached a primary safety or efficacy 
endpoint, and at latest contact 91% of patients were 
on no anticoagulant or antiplatelet medication and 
9% still acetylsalicylic acid (Table 4). The patients 
were asked for clinical symptoms of AF and all 
postinterventional ECGs were screened for AF. 
No patient had developed AF.
Discussion
Atrial fibrillation is the most common sus-
tained cardiac arrhythmia [25] and is associated 
with substantial mortality and morbidity, particu-
larly due to stroke [26]. ASD closure is advocated 
for prevention of stroke (paradoxical or secondary 
to AF) or heart failure due to volume overload. 
PFO closure is used for prevention of paradoxical 
Table 1. Baseline characteristics (n = 13).
Characteristics
Age [years] 58.2 ± 9.1
Body mass index [kg/m2] 27.0 ± 4.4
Women 7 (54%)
CHADS2 score 1.2 ± 1.3
CHA2DS2-VASc score 1.92 ± 1.7
HAS-BLED score 0.85 ± 1.1
Atrial rhythm (including history)
Atrial fibrillation (paroxysmal  
or permanent)
0 (0%)
Atrial flutter 0 (0%)
Clinical features
Prior ischemic stroke 3 (23%)
Coronary artery disease 0 (0%)
Valvular heart disease 0 (0%)
Renal function (mean eGFR,  
in mL/min/1.73 m2)
97 ± 24
Anti-thrombotic therapy prior to laac
Acetylsalicylic acid 3 (23%)
Platelet inibitors other than  
acetylsalicylic acid
0 (0%)
Chronic oral anticoagulation 0 (0%)
Echocardiographic data
Systolic left ventricular  
ejection fraction [%]
65 ± 2
Left atrial diameter (PLAX echo, mm) 42 ± 5
Values are number (%) or mean ± standard deviation; eGFR —  
estimated glomerular filtration rate; PLAX — parasternal long axis
Table 2. Intervention (n = 13).
Procedural characteristics
Flouroscopy time [min] 16 ± 8
Amplatzer Cardiac Plug 6 (20 ± 3,  
16–24 mm)
Amplatzer Amulet Occluder 7 (21 ± 4,  
16–25 mm)
Amplatzer Septal Occluder 10 (34 ± 6,  
24–40 mm) 
Amplatzer Cribriform Occluder 1 (30 mm)
Amplatzer PFO Occluder 2 (25 mm)
Implantation attempts 1.0 ± 0.0
Concomittant procedures
Coronary angiography 12 (92%)
Perirocedural success  
and adverse events
Procedural success 13 (100%)
Combined safety endpoint* 0 (0%)
*Composite of death, stroke, clinically relevant pericardial effusion, 
VARC-2 life-threatening or major bleeding, VARC-2 major access 
vessel complication, device embolization, VARC-2 severe kidney in-
jury, or bailout surgery. Values are number (%) or mean ± standard 
deviation; PFO — patent foramen ovale; VARC — Valve Academic 
Research Consortium
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Table 3. Postprocedural data and follow-up 
transesophageal echocardiography (TEE).
Post procedure in-hospital (n = 13)
Hospital stay [days] 0.8 ± 0.4
Same day discharge 4 (31%)
Pericardial effusion 0 (0%)
Antithrombotic therapy (n = 13)
Acetylsalicylic acid 12 (92%)
Platelet inibitors other than  
acetylsalicylic acid
12 (92%)
Dual antiplatelet therapy 12 (92%)
Vitamin K antagonists 0 (0%)
Non vitamin K dependant  
oral anticoagulants 
0 (0%)
TEE (n = 10)
Duration from intervention [months] 6.7 ± 2.0
All devices in correct position 10 (100%) 
Late pericardial effusion 0 (0%)
Late device embolization 0 (0%)
Device thrombus (any) 0 (0%)
Procedural success at TEE follow-up 8 (100%)
Shunt or leak > 5 mm 1 (10%)
Shunt or leak < 5 mm 2 (20%)
Values are number (%) or mean ± standard deviation.
Table 4. Clinical follow-up (n = 13).
Long-term clinical follow-up 13 (100%)
Duration from procedure [years] 2.0 ± 0.8
Antithrombotic therapy
Acetylsalicylic acid 1 (9%)
Other platelet inibitors 0 (0%)
Dual antiplatelet therapy 0 (0%)
Vitamin K antagonists 0 (0%)
Non vitamin K dependant  
oral anticoagulants
0 (0%)
Clinical outcome
All-cause death 0 (0%)
All-cause stroke 0 (0%)
All-cause transient ischemic attack 0 (0%)
Myocardial infarction 0 (0%)
Systemic embolism 0 (0%)
Venous thrombosis/ 
/pulmonary embolism
0 (0%)
Fatal, lifethreatening, or major bleeding 0 (0%)
Hospitalization 0 (0%)
Primary safety endpoint 0 (0%)
Primary efficacy endpoint 0 (0%)
Values are number (%) or mean ± standard deviation.
stroke. LAA closure is indicated for prevention of 
stroke or bleeding in patients with AF [13–18].
The present study reports the feasibility and 
safety of “primary primary” preventive LAA closure 
during percutaneous ASD or PFO closure in patients 
with enlarged atria but no AF. It proved technically 
successful and safe but efficacy of our approach 
cannot be determined. No patient developed AF 
and therefore the potential of preventing embolic 
ischemia or bleeding because of the obviated need 
for oral anticoagulation remains unknown.
A large nationwide study of Nyboe et al. 
[21] included 1168 patients with ASD who were 
followed-up over a long-term period. The risk of 
developing AF was up to 10-fold in comparison 
to the general population. In case of conservative 
management, the stroke risk was 2.6-fold. In case 
of ASD closure, the stroke risk was reduced to 
2-fold. This can be due to both, the elimination of 
paradoxical embolism and the reduction of atrial 
sizes. Yet, the risk of AF-associated stroke remains 
elelvated [21]. 
Atrial fibrillation with the need for COA is ex-
pected to occur with a certain frequency in patients 
at some point in time after septal defect closure 
while they were still in sinus rhythm [9, 27]. Age 
> 40 years is a well-known risk factor for AF after 
ASD closure [28]. Moreover, ASD closure devices 
can trigger new-onset AF in the early phase. In the 
later phase they may reduce the risk of AF as the 
atria shrink after elimination of the shunt [10, 11]. 
Large devices in the interatrial septum may render 
percutaneous LAA closure intricate or downright 
impossible. 
Chronic oral anticoagulation has been proven 
to effectively prevent thromboembolic strokes 
but there is a risk of serious bleeding which de-
ters many patients from taking this therapy [29]. 
Therefore, alternative treatment options for stroke 
prevention in patients with AF with increased 
stroke risk are needed. Closure of the LAA has 
emerged as promising [13, 30].
Left atrial appendage closure in the sense of 
“primary primary” prevention has the potential to 
avoid future strokes in case new-onset AF goes 
undetected on top of the potential to avoid major 
bleeding in case a patient requires COA for AF 
during follow-up. However as is inherent to every 
preventive intervention, the risk and cost of the 
combined and partially preventive intervention 
may become unjustified, in case AF never develops 
during follow-up. This concern is alleviated by the 
safety of such an approach which is apparent from 
these data.
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Limitations of the study
The study has several limitations. It is a ret-
rospective study and not a randomized trial and 
therefore selection bias is evident. The sample 
size is small. Furthermore, none of these patients 
developed AF during the relatively short observa-
tion period. More patients and longer follow-up are 
required to derive a clinically important message.
Conclusions
This study demonstrates feasibility of “pri-
mary primary” preventive LAA closure during 
percutaneous closure of large ASDs or PFOs with 
atrial enlargement in patients without AF. In this 
series no adverse safety events occurred. The idea 
is to prepare such patients for the likely event of 
later AF. ASD closure alone with a large septal 
device renders it difficult if not impossible to later 
perform a transseptal puncture for LAA closure. 
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